MULTIDETECTOR COMPUTED TOMOGRAPHY IMAGING FEATURES AND OVERALL SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED AT K HOSPITAL
Main Article Content
Abstract
Objectives: To describe the clinical and laboratory characteristics, multi-detector computed tomography (MDCT) features, and overall survival of patients with hepatocellular carcinoma (HCC) treated at K Hospital.
Materials and Methods: A cross-sectional descriptive study with longitudinal follow-up was conducted on 307 patients diagnosed with hepatocellular carcinoma at K Hospital from January 2020 to December 2020 (with follow-up until August 2022).
Results: The majority of patients were in the 41-60 age group (51.8%), male (88.6%), with a normal performance status (91.9%), and a background of chronic hepatitis B infection (81.4%). Regarding tumor characteristics, the mass-forming type accounted for 99.3%, with 67.1% located in the right lobe; most were solitary tumors (56.7%), and 44.3% had a size ranging from 3-7 cm. On MDCT, 74.6% showed decreased attenuation pre-contrast, and 89.3% exhibited typical post-contrast enhancement. Regarding disease staging, most patients were at the intermediate stage (BCLC B) at 61.6%, followed by BCLC A (17.9%), while only 8 cases were at the terminal stage (BCLC D). The mortality rate was 53.7% (165/307). The highest overall survival was observed in the group with tumor size ≤ 3 cm (mean 28.66 months) and the solitary tumor group (mean 23.21 months). The mean survival time for BCLC stage A was approximately 30 months, stage B was 20 months, while stage D was only 5.6 months (p < 0.05).
Conclusion: Although newly diagnosed, most patients with hepatocellular carcinoma were already in the intermediate to advanced stages, resulting in low survival rates.
Article Details
Keywords
Computed tomography, survival time, hepatocellular carcinoma (HCC).
References
2. Mauro E, de Castro T, Zeitlhoefler M, et al. (2025). Hepatocellular carcinoma: Epidemiology, diagnosis and treatment. JHEP Rep, 7(12), 101571.
3. Hoàng Văn Hưng, Lập NQ (2023). Nghiên cứu đặc điểm hình ảnh ung thư biểu mô tế bào gan nguyên phát trên cắt lớp vi tính và một số yếu tố liên quan. Tạp chí Y học Việt Nam, 527(6), 233-238.
4. Nguyễn Văn Nam , Nguyễn Phước Bảo Quân , Huỳnh Minh Phú (2023). Nghiên cứu đặc điểm hình ảnh và giá trị của hình ảnh cắt lớp vi tính trong chẩn đoán ung thư biểu mô tế bào gan tại Bệnh viện Ung bướu Thành phố Cần Thơ năm 2021-2023. Tạp chí Y Dược học Cần Thơ, 63,
5. Lavarone M, Alimenti E, Canova L, et al. (2025). The impact of BCLC recommendations on survival for patients with hepatocellular carcinoma. Hepatol Commun, 9(8),
6. Trần Thoại Uyên, Võ Hồng Minh Công, Trần Thị Thu Cúc, Nguyễn Ngọc Tường Vy, Nguyễn Thị Huyền Trâm (2022). Các yếu tố ảnh hưởng đến sống còn 5 năm trên bệnh nhân ung thư biểu mô tế bào gan tại Bệnh viện Nhân dân Gia Định. Tạp chí Y Dược học Phạm Ngọc Thạch, 1(2), 220-227.
7. Liapis I, Ziogas IA, Theocharopoulos C, et al. (2025). Re-evaluating surgical strategies in Barcelona Clinic Liver Cancer-B hepatocellular carcinoma. World J Hepatol, 17(9), 108970.
8. Ho KKY, Chiang CL, Wong T, et al. (2025). Survival impact of conversion therapy for Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma-a propensity score matching analysis. Hepatobiliary Surg Nutr, 14(6), 1063-1077.
9. Yilma M, Houhong Xu R, Saxena V, et al. (2024). Survival Outcomes Among Patients With Hepatocellular Carcinoma in a Large Integrated US Health System. JAMA Netw Open, 7(9), e2435066.